Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts ...

FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin ...

Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in ...

FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix's investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin Deficien ...
Cfr.org

Three Years of War in Ukraine: Are Sanctions Against Russia Making a Difference?

The United States and its allies have imposed broad economic penalties on Russia over its war in Ukraine. As the conflict continues, experts debate whether the sanctions are working. Since Russia ...
ABC News

Key moments in case of Des Moines school superintendent arrested by ICE: Timeline

Ian Roberts had a final order of removal issued in 2024, ICE said. The arrest of the superintendent of Iowa's largest school district by Immigration and Customs Enforcement officers has become a ...
Santé log

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised

Group sales In the first nine months of 2025, Roche achieved sales growth of 7% (2% in CHF) to CHF 45.9 billion due to strong demand for our pharmaceutical and diagnostic products.